https://www.fresenius.com en-us Tue, 12 Nov 2024 16:00:00 +0100 Tue, 12 Nov 2024 16:00:00 +0100 Tue, 12 Nov 2024 16:00:00 +0100 <![CDATA[mAbxience and Egis announce strategic commercialization agreement for biosimilar candidates in Central and Eastern Europe]]> Wed, 06 Nov 2024 14:00:00 +0100 <![CDATA[Fresenius Q3/24: Simplification and focus drives sustained performance – Outlook upgraded]]> Wed, 16 Oct 2024 16:00:00 +0200 <![CDATA[Fresenius and Cellular Origins announce development agreement for Cell and Gene Therapy Manufacturing]]> Fri, 11 Oct 2024 15:30:00 +0200 <![CDATA[Fresenius returns to the Swiss bond market with successful issue of CHF 225 million]]> Thu, 03 Oct 2024 20:30:00 +0200 <![CDATA[mAbxience and Teva announce second strategic global license agreement for biosimilar oncology treatment candidate]]> Mon, 30 Sep 2024 23:45:00 +0200 <![CDATA[Fresenius successfully completes divestment of Vamed’s rehabilitation business]]> Mon, 30 Sep 2024 13:30:00 +0200 <![CDATA[U.S. FDA Approval for OtulfiTM*, an Ustekinumab Biosimilar]]> Fri, 27 Sep 2024 15:00:00 +0200 <![CDATA[European Commission Approval for FYB202, an Ustekinumab Biosimilar]]> Tue, 24 Sep 2024 21:00:00 +0200 <![CDATA[Nick Stone appointed Head of Investor Relations at Fresenius]]> Mon, 16 Sep 2024 19:00:00 +0200 <![CDATA[Key parameter for the 2025 DRG inflator for German hospitals set at 4.41% ]]> Mon, 02 Sep 2024 16:00:00 +0200 <![CDATA[Fresenius divests IV manufacturing site in Chile]]> Tue, 27 Aug 2024 20:00:00 +0200 <![CDATA[Fresenius Kabi expands women’s health portfolio with new generic]]> Wed, 31 Jul 2024 13:00:00 +0200 <![CDATA[Fresenius with excellent performance in Q2 – Major progress on deleveraging on the back of strong cash flow: Entering target ratio corridor – Outlook confirmed and optimistic about second half]]> Fri, 26 Jul 2024 17:57:10 +0200 <![CDATA[Positive CHMP Opinion for FYB202, an Ustekinumab Biosimilar Candidate ]]> Thu, 11 Jul 2024 15:00:00 +0200 <![CDATA[Fresenius Announces EMA Acceptance for Review of Denosumab Biosimilar Candidates]]> Tue, 02 Jul 2024 20:00:00 +0200 <![CDATA[Fresenius continues (Bio)Pharma momentum: Tyenne now available in subcutaneous form in the U.S.]]> Thu, 27 Jun 2024 14:00:00 +0200 <![CDATA[Fresenius publishes its first Sustainability Highlights Report]]> Tue, 18 Jun 2024 20:30:00 +0200 <![CDATA[#FutureFresenius is paying off: S&P Global Ratings revises outlook for Fresenius SE from negative to stable, rating affirmed at BBB ]]> Wed, 05 Jun 2024 17:00:00 +0200 <![CDATA[Fresenius outlines growth strategy for its Care Provision Platform – improved Fresenius Helios’ FY/24 outlook and raised ambitions]]> Mon, 27 May 2024 20:00:00 +0200 <![CDATA[Fresenius Announces FDA Acceptance for Review of Denosumab Biosimilar Application]]>